Drug intelligence / Profile preview

ICTP-501

Development stage: Preclinical
Lead developer: InnoCure Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

ICTP-501 is a preclinical-stage molecular glue degrader being developed by InnoCure Therapeutics, a South Korean biotechnology company. Utilizing targeted protein degradation (TPD) technology, ICTP-501 is designed to induce the degradation of specific, currently undisclosed protein targets that are traditionally considered 'undruggable.' The compound is being investigated for the treatment of various cancers, including solid tumors and hematological malignancies. As a molecular glue, it functions by facilitating and stabilizing the proximity between an E3 ubiquitin ligase and a target protein, leading to the target's ubiquitination and subsequent degradation by the 26S proteasome.

Beyond the preview

Go deeper on ICTP-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICTP-501.

Explore the full profile